Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Scavelli

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Tumori|April 11, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer RegistryLuca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, et al.
Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Translational Medicine|August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final resultsGaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Oncotarget|August 31, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Tumori|April 11, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer RegistryLuca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, et al.
Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Translational Medicine|August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final resultsGaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Oncotarget|August 31, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 2